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patient reported outcomes as a measure of quality of clinician
reported outcomes appears to be a feasible tactic in a site-based
ratings surveillance quality assurance system.
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OBJECTIVE: Major depressive disorder (MDD) is a leading
cause of disability worldwide. This study analyzed the literature
describing the burden of MDD in North America (USA and
Canada), with particular focus on patients with treatment-
resistant depression (TRD). METHODS: Systematic searches
were conducted of English-language papers published between
1987 and 2007, utilizing MEDLINE, EMBASE, and the
Cochrane Library, relevant websites, and hand searches. Major
areas for review were the humanistic and economic burden of
MDD. Additional areas for analysis included treatment options
and costs, treatment efﬁcacy and response rates, treatment guide-
lines, and reimbursements. RESULTS: A total of 908 articles
were identiﬁed, of which 107 studies from North America ful-
ﬁlled the inclusion criteria (humanistic burden, N = 45; economic
burden, N = 49; and treatment guidelines, N = 13). Analysis of
these studies identiﬁed an increased humanistic and economic
burden in patients with MDD and TRD in North America. MDD
was associated with a high prevalence (3–31%), was chronic in
nature, and had a high frequency of comorbid mental disorders.
Health-related quality of life (HRQL) instruments identiﬁed a
signiﬁcant negative impact from MDD, including domains of
mental well-being (independence, alertness, role emotional,
personal/spiritual beliefs) and perceived physical functioning
(energy and fatigue, bodily care). In a study that compared
HRQL in responders and non-responders to therapy, HRQL was
signiﬁcantly lower in non-responders (P < 0.001). Patients with
TRD were particularly severely affected, through higher medical
costs and greater losses in work productivity. CONCLUSION:
Patients with MDD and their families suffer greater humanistic
and economic burden than healthy individuals. Treatment
reduces the burden of MDD, although current evidence-based
guidelines for MDD offer limited recommendations on the choice
of pharmacological treatments based on their potential to reduce
burden of illness and resource use.
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OBJECTIVE: Though antipsychotics were originally developed
to treat schizophrenia, their use in older adults with dementia has
grown substantially. Given concern about the safety of these
drugs, we assessed the impact of a prior authorization (PA) policy
upon use and choice of antipsychotic medication in long-term
care. METHODS: We conducted a retrospective cohort study
using administrative data from two Canadian provinces—one in
which access to newer antipsychotics (risperidone, olanzapine,
and quetiapine) was unrestricted (Ontario), and another in which
access required PA (British Columbia (BC)). Subjects were all
37,057 Ontario and 13,569 BC residents aged 66 years or older
who were newly admitted to a nursing home between April 1,
1998 and March 31, 2002, who had no history of schizophrenia
or psychosis in the 5 years preceding admission, and who had no
evidence of antipsychotic drug use in the preceding year. We
assessed crude and adjusted exposure to antipsychotic medica-
tion over the year following nursing home admission, as well as
the types of medications used. RESULTS: Nineteen percent of
Ontario residents were newly dispensed an antipsychotic within
100 days of nursing home admission vs. 16% in BC. Male sex,
younger age, fewer comorbidities, and history of dementia all
were strongly associated with receipt of an antipsychotic. Adjust-
ment for these factors reduced the cross-provincial difference in
drug use. However, fewer BC residents received newer anti-
psychotics, particularly after risperidone received an approved
indication for the management of behavioural symptoms of
dementia. Olanzapine, which required PA throughout the study,
was dispensed to 11% and 3% of Ontario and BC residents,
respectively. CONCLUSION: Although BC’s PA policy had neg-
ligible impact upon the incidence of antipsychotic drug use as a
whole, it appeared to inﬂuence drug choice. Questions remain
about the impact of such policies upon health outcomes and
costs.
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OBJECTIVE: The 2002 Veterans Health Care Act raised medi-
cation copayments from $2 to $7 for lower priority patients.
Veterans with schizophrenia constitute a multiply disadvantaged
population; 40% are antipsychotic non-adherent, substantially
increasing psychiatric admission risks. Certain patient sub-
groups might be particularly sensitive to medication costs with
signiﬁcant clinical ramiﬁcations. Diverse cultural expressions of
health beliefs and priorities contribute additional layers of com-
plexity. This study examines potential inequities stemming from
higher copayments. METHODS: All veterans with schizophrenia
were followed 33 months Pre and Post copayment increase.
Longitudinal models analyzed effects of higher medication costs
in copayment veterans versus a natural control group of exempt
patients, controlling for demographics, substance abuse, func-
tional status, and other comorbidities. Adjusted means compared
prescription patterns and inpatient utilization among four ethnic
groups: white (N = 36,452), African-American (N = 17,602),
Hispanic (N = 5,225), and Other (N = 10,707). RESULTS:
African-Americans were relatively younger with higher substance
abuse rates. Hispanic veterans were more likely to be unmarried
and have multiple illnesses, though fewer (39%) faced copay-
ments than other patients. Minorities ﬁlled 10–35% fewer pre-
scriptions than white veterans, and ethnic differences were
evident in pharmacy ﬁlls and inpatient days. White veterans
reduced psychotropic ﬁlls 15% after the policy change, decreas-
ing hospital days by nearly the same amount. However, mi-
norities dropped psychotropics 19%–22% while subsequently
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increasing inpatient utilization, the latter especially true for His-
panics. CONCLUSION: Although all veterans dramatically
adjusted pharmacy use following the copayment change, ethnic
minorities appeared particularly sensitive to drug costs. Similarly,
while white veterans appeared to reduce psychotropic use with
minimal consequences, minorities experienced substantially
elevated admission risks associated with lower cost-related
adherence. Beneﬁt changes for veterans with chronic conditions
should be implemented cautiously and carefully evaluated. Rec-
onciling budgetary concerns with quality care provision requires
sensitive attention to unique patient groups to ensure equity
while minimizing economic and health disparities.
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OBJECTIVE: To compare clinical characteristics of patients ini-
tiating treatment on duloxetine vs. those initiating on venlafaxine
XR, escitalopram, and ﬂuoxetine over a two year period.
METHODS: Retrospective claims analysis of Pharmetrics
managed care health plan patients initiating on select antidepres-
sants between September 1, 2004 and August 31, 2006. A total
of 798,259 patients were assigned to cohorts based on their most
recent antidepressant prescription. Cochran-Mantel-Haenszel
test was used to test the proportional differences among the
four cohorts. RESULTS: Overall, 72.1% of study patients were
female with a mean age of 44.3 years. Demographic differences
between cohorts were modest. Based on comparison of medical
claims within +/-30 days of initiation on venlafaxine XR, escit-
alopram, and ﬂuoxetine, respectively, duloxetine initiators were
more likely to have visited a mental health specialist (24.2% vs.
18.2%, 18.6%, and 16.5%) and been diagnosed with depression
(29.2% vs. 24.1%, 25.4%, 24.9%). Among the depressed,
duloxetine patients were more frequently diagnosed with major
depressive disorder (MDD) (52.8% vs. 44.3%, 40.5%, and
36.4%) and, among those diagnosed with MDD, were more
frequently diagnosed with recurrent MDD (78.2% vs. 73.8%,
66.2%, and 64.1%). Duloxetine initiators were more frequently
diagnosed with a pain condition (44.8% vs. 27.7%, 27.3%,
and 24.9%) , particularly for back (15.5% vs. 7.5%, 7.0%, and
6.3%) or musculoskeletal pain (28.2% vs. 15.5%, 14.4%. and
13.1%), and were more likely to have been treated previously
with a narcotic analgesic (24.2% vs. 11.1%, 9.8%, and 9.2%)
(p < 0.05 for all reported differences). CONCLUSION: Dulox-
etine patients are more likely to present with more severe depres-
sion diagnoses and pain than patients on other antidepressants.
Case mix adjustments should be made when comparing out-
comes and costs associated with treatment with different antide-
pressants. These ﬁndings are broadly consistent with earlier
analyses of data from the ﬁrst four months following introduc-
tion of duloxetine in the U.S.
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OBJECTIVE: To assess month-by-month changes in clinical
characteristics of patients initiating on duloxetine, a new anti-
depressant, during the ﬁrst two years following its initial avail-
ability in the United States. METHODS: Retrospective claims
analysis of Pharmetrics managed care health plan patients ini-
tiating on duloxetine between September 1, 2004 and August
31, 2006. A total of 102,567 duloxetine initiators were identi-
ﬁed for inclusion in this study. Monthly data series for demo-
graphic and clinical characteristics were created on the basis of
Cymbalta initiation date. Claims within +/-30 days of initiation
were used to identify clinical characteristics. RESULTS: Demo-
graphic patterns of patients initiating on duloxetine remained
stable over the two year period (average monthly percent female
73.0%; average monthly age 47.4 years), as did proportions of
patients with any anxiety (20.7%) or a GAD diagnosis (5.6%).
The average monthly % of patients treated by mental health
specialists trended downward over the ﬁrst 16 months of the
study period (from 32.3% to 23.7%), while the % with a
depression diagnosis trended downward (51.0% to 45.4%) for
the ﬁrst 12 months, before stabilizing thereafter. The % of
patients with a pain diagnosis increased over the ﬁrst three
months (62.4% to 66.6%) and remained stable thereafter. Of
those with a depression diagnosis, the % with an MDD diag-
nosis trended downward (55.8% to 45.8%) for 15 months
before stabilizing, while the % of those with MDD diagnosed
with Recurrent MDD remained stable over the entire study
period (77.8%). CONCLUSION: Demographic characteristics
of patients initiating on duloxetine in the two years following
initial availability in the United States have remained relatively
stable. Clinical characteristics have shown some variation, par-
ticularly over the ﬁrst 12 to 16 months following initial avail-
ability. These trends in utilization have implications for the
selection of appropriate methodologies for developing cohorts
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OBJECTIVE: There has been a rapid increase in the use of
atypical antipsychotics in pediatric populations over the past few
years. Most of these drugs are unapproved in pediatric popula-
tions. Study objectives were: 1) To identify the trend of new users
of atypical antipsychotics in the Arkansas Medicaid population
under the age of 18 for years 2001 through 2005; 2) to classify
the use of each atypical antipsychotic as evidence-based or not
depending on the diagnoses for which it was prescribed; and 3) to
determine which pediatric patients are more likely to receive an
evidence-based atypical antipsychotic prescription. METHODS:
Study was a retrospective database analysis of Arkansas Medic-
aid for the period from January 2000 to December 2006. Par-
ticipants were the subjects under 18 years of age, with their ﬁrst
atypical antipsychotic prescription claim between 2001 and
2005, with no prior antipsychotic use and having a continuous
two-year Medicaid enrollment. Main outcome measure was the
proportion of study cohort with at least one evidence-based
atypical antipsychotic prescription claim, which was deﬁned as
any use of atypical antipsychotic supported by a clinical study in
the literature. RESULTS: The ﬁnal study cohort was 11,700. The
trend of new pediatric users of atypical antipsychotic therapy
increased from 1482 to 3110 new atypical users from 2001 to
2005. After identifying 86 clinical studies from the literature and
deﬁning the evidence-based use for each atypical antipsychotic, it
was found that 41.32% of the new pediatric users did not have
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